| Primary |
| Acne |
19.9% |
| Ill-defined Disorder |
11.4% |
| Pneumonia |
10.9% |
| Pain |
6.2% |
| Cellulitis |
5.7% |
| Anaesthesia |
4.7% |
| Asthma |
4.3% |
| Infection |
3.8% |
| Bronchitis |
3.3% |
| Hypertension |
3.3% |
| Antibiotic Therapy |
2.8% |
| Arthritis |
2.8% |
| Postoperative Wound Infection |
2.8% |
| Prophylaxis |
2.8% |
| Subcutaneous Abscess |
2.8% |
| Vaginal Infection |
2.8% |
| Depression |
2.4% |
| Hyperpyrexia |
2.4% |
| Lung Abscess |
2.4% |
| Sinusitis |
2.4% |
|
| Drug Hypersensitivity |
8.4% |
| Drug Ineffective |
8.4% |
| Rash |
8.4% |
| Product Quality Issue |
7.4% |
| Paralysis Flaccid |
6.3% |
| Pruritus |
6.3% |
| Product Odour Abnormal |
5.3% |
| Urticaria |
5.3% |
| Diarrhoea |
4.2% |
| International Normalised Ratio Increased |
4.2% |
| Laryngeal Oedema |
4.2% |
| Stevens-johnson Syndrome |
4.2% |
| Tachycardia |
4.2% |
| Toxic Skin Eruption |
4.2% |
| Abortion Spontaneous |
3.2% |
| Bone Marrow Failure |
3.2% |
| Hypersensitivity |
3.2% |
| Infection |
3.2% |
| Muscle Spasms |
3.2% |
| Nausea |
3.2% |
|
| Secondary |
| Product Used For Unknown Indication |
55.3% |
| Infection |
7.3% |
| Ill-defined Disorder |
5.9% |
| Pyrexia |
5.4% |
| Constipation |
4.6% |
| Anaesthesia |
2.4% |
| Abdominal Infection |
2.2% |
| Hypertension |
2.2% |
| Fungal Infection |
2.1% |
| Acne |
1.8% |
| Pneumonia |
1.6% |
| Psoas Abscess |
1.5% |
| Postoperative Wound Infection |
1.3% |
| Staphylococcal Infection |
1.1% |
| Candida Infection |
1.0% |
| Candidiasis |
1.0% |
| Endocarditis |
1.0% |
| Induction Of Anaesthesia |
1.0% |
| Pain |
0.8% |
| Cellulitis |
0.7% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
28.7% |
| Toxic Epidermal Necrolysis |
8.0% |
| Renal Failure Acute |
6.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.7% |
| Pain |
5.7% |
| Rash |
5.7% |
| Hypotonia |
4.6% |
| Drug Hypersensitivity |
3.4% |
| Drug Ineffective |
3.4% |
| Lymphocyte Stimulation Test Positive |
3.4% |
| Product Quality Issue |
3.4% |
| Death |
2.3% |
| Drug Eruption |
2.3% |
| Granulocytopenia |
2.3% |
| Hypersensitivity |
2.3% |
| Jaundice |
2.3% |
| Liver Disorder |
2.3% |
| Multi-organ Failure |
2.3% |
| Nausea |
2.3% |
| Oesophagitis |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.2% |
| Drug Use For Unknown Indication |
9.9% |
| Prophylaxis |
7.2% |
| Hypertension |
6.3% |
| Acne |
4.8% |
| Pain |
4.6% |
| Infection Prophylaxis |
4.0% |
| Diabetes Mellitus |
3.2% |
| Constipation |
2.9% |
| Hiv Infection |
2.9% |
| Nausea |
2.4% |
| Non-small Cell Lung Cancer |
2.4% |
| Premedication |
1.9% |
| Bone Marrow Conditioning Regimen |
1.8% |
| Breast Cancer |
1.8% |
| Crohn's Disease |
1.7% |
| Insomnia |
1.7% |
| Pyrexia |
1.6% |
| Infection |
1.4% |
| Prophylaxis Against Graft Versus Host Disease |
1.4% |
|
| White Blood Cell Count Decreased |
18.7% |
| Vomiting |
8.4% |
| Pain |
6.5% |
| Pneumonia |
6.5% |
| Pulmonary Embolism |
4.7% |
| Rhabdomyolysis |
4.7% |
| Sepsis |
4.7% |
| Septic Shock |
4.7% |
| White Blood Cell Count Increased |
4.7% |
| Hypertension |
3.7% |
| Pleural Effusion |
3.7% |
| Pneumothorax |
3.7% |
| Renal Failure |
3.7% |
| Stomatitis |
3.7% |
| Thrombocytopenia |
3.7% |
| Cerebral Infarction |
2.8% |
| Eczema |
2.8% |
| Gallbladder Disorder |
2.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.8% |
| Pancytopenia |
2.8% |
|
| Interacting |
| Subcutaneous Abscess |
15.8% |
| Depression |
10.5% |
| Abdominal Pain |
5.3% |
| Anaemia |
5.3% |
| Ankylosing Spondylitis |
5.3% |
| Asthma |
5.3% |
| Dermatitis |
5.3% |
| Dyspepsia |
5.3% |
| Extrapyramidal Disorder |
5.3% |
| Hypertension |
5.3% |
| Irritable Bowel Syndrome |
5.3% |
| Schizophrenia |
5.3% |
| Acne |
2.6% |
| Headache |
2.6% |
| Localised Infection |
2.6% |
| Migraine Prophylaxis |
2.6% |
| Muscle Spasms |
2.6% |
| Obesity |
2.6% |
| Pain |
2.6% |
| Tetanus Immunisation |
2.6% |
|
| White Blood Cell Count Decreased |
66.7% |
| Withdrawal Syndrome |
33.3% |
|
